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Abstract
Cardiovascular disease (CVD) comprises a vast spectrum of disease states ranging from 
hypertension (HTN) to valvular heart disease (VHD). CVD is known to be the lead‐
ing cause of morbidity, mortality, and health‐care expenditure throughout the world. 
According to the World Health Organization, coronary artery disease (CAD) and stroke, 
both subsets of CVD, are the world’s biggest killers, accounting for a combined 15 mil‐
lion deaths in 2015. These diseases have remained the leading causes of death globally in 
the last 15 years. In 2010, CAD alone was projected to cost the U.S. $108.9 billion includ‐
ing the cost of health‐care services, medications, and lost productivity. The presence of 
frailty significantly worsens outcomes for patients suffering from CAD. With just this one 
example of how frailty affects CVD, it is clear that understanding the impact of frailty 
upon patients afflicted with the spectrum of cardiovascular disease is integral for the care 
of this very significant patient population.
Keywords: frailty, cardiovascular disease, valvular heart disease, outcomes in cardiovascular 
disease, hypertension, coronary artery disease, peripheral vascular disease, lipid dysregulation
1. Introduction
Cardiovascular disease (CVD) comprises a vast spectrum of disease states ranging from hyper‐
tension (HTN) to valvular heart disease (VHD) and is known to be the leading cause of mor‐
bidity, mortality, and health‐care expenditure throughout the world. According to the World 
Health Organization, coronary heart disease (CHD) and stroke, both subsets of CVD, are the 
world’s most impactful causes of mortality, accounting for a combined 15 million deaths in 
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2015. These diseases have remained the leading causes of death globally in the last 15 years. In 
2010, CHD alone was projected to cost the United States (US) $108.9 billion including the cost 
of health‐care services, medications, and lost productivity. The presence of frailty significantly 
worsens outcomes for patients suffering from CHD [1]. With just this one example of how 
frailty affects CVD, it is clear that understanding the impact of frailty upon patients afflicted 
with the spectrum of CVD is integral for the care of this very significant patient population.
While frailty as an entity is manifested by the interplay of multiple factors, there are some 
that are pertinent to the relationship between CVD and frailty. Endocrine dysregulation and 
higher levels of inflammatory markers have been found in frail compared with non‐frail per‐
sons, and these derangements have been appreciated in patients with CHD. Elevations in 
some markers of frailty are also risk factors for the development of progressive vascular and 
CHD [2]. So while it can be inferred that CVD and frailty share common links, the effect of 
frailty upon the outcomes of CVD is still an area of interest and continued study [3].
We now know that CVD can worsen sarcopenia and lead to frailty, while frailty worsens 
morbidity and mortality in CVD [4, 5]. Maximal aerobic power (MAP), a measure of frailty, 
decreases with age due to a decrease in cardiac output. And though CVD is not the primary 
cause of decline of MAP, CVD clearly exacerbates the said decline [5]. Recently, in a meta‐
analysis of 54,250 elderly individuals with a mean follow‐up of 6.2 years, the presence of ath‐
erosclerotic CVD was associated with the coexistence of frailty syndrome (FS) with an odds 
ratio (OR) of 2.7–4.1 [6]. Also, in patients who did not begin the study with FS, CVD was asso‐
ciated with the onset of FS during follow‐up of these patients. There have been several studies 
that highlight the relationship between CVD and frailty, as described in Tables 1 and 2.
Study Study type/number of 
patients
Objective Outcome
Chin  
et al. [7]
Population‐based cohort 
study/545 men
Assess association between classic 
cardiovascular risk factors and subsequent 
functional disability and mental well‐being 
in elderly men.
Combined classic 
cardiovascular risk factors 
are predictive of functional 
disability.
Newman 
et al. [8]
Observational cohort/4375 
patients
Assess the relationship between subclinical 
cardiovascular disease and frailty.
Cardiovascular disease was 
associated with an increased 
likelihood of frail health.
Chaves  
et al. [9]
Prospective population 
based cohort/670 patients
Examined the cross‐sectional relationship 
between hemoglobin (Hb) and a 
recently‐validated measure of frailty in 
community‐dwelling older women, and 
whether this relationship was modified by 
cardiovascular disease (CVD) status.
Mildly low and low‐normal 
Hb levels were independently 
associated with increased 
frailty risk. This risk was 
synergistically modified by 
the presence of CVD.
Woods  
et al. [10]
Prospective study, the 
Women’s Health Initiative 
Observational Study/40.657 
women
Identified risk factors for frailty as targets 
for prevention. Investigated the predictive 
validity of this frailty classification for 
death, hospitalization, hip fracture, and 
activity of daily living (ADL) disability.
Community‐dwelling 
older women with CVD 
and cardiovascular risk 
factors were at higher risk of 
developing incident frailty.
Table 1. Effect of cardiovascular disease on frailty.
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A scoring system easily used on an inpatient basis highlights the interplay of CVD and 
frailty [16]. Sanchis et al. described seven independent predictors of frailty: age ≥75 years, 
female sex, prior CHD, admission for heart failure (HF), hemoglobin ≤12.5 g/dL, vitamin D 
≤9 ng/mL, and cystatin‐C ≥1.2 mg, which could be measured on an inpatient basis. Defining 
frailty as positive when there were ≥3 had a good correlation with the Fried score of frailty.
In this chapter, we delve into a basic understanding of the underlying pathophysiology of 
CVD in relation to frailty and how it is worsened by the latter, inflammatory markers that 
have proven significant in CVD and frailty, and how frailty affects a vast spectrum of CVD, 
ranging from lipid dysregulation to outcomes in VHD.
Study Study type/ 
number of patients
Objective Outcome
Klein  
et al. [11]
Prospective 
cohort/2962 patients
Association of measures of frailty to 
disease outcomes and survival in a 
population‐based study of Midwestern 
adults.
Greater frailty was significantly 
associated with cardiovascular disease 
and hypertension.
Cacciatore 
et al. [12]
Prospective 
cohort/1259 patients
This study aimed to examine the 
predictive role of frailty on long‐term 
mortality in elderly subjects with CHF.
Frailty represents a new independent 
variable for predicting long‐term 
mortality in elderly subjects with CHF.
Purser  
et al. [13]
Observational 
cohort/309 patients
To characterize physiological variation 
in hospitalized older adults with severe 
coronary artery disease (CAD) and 
evaluate the prevalence of frailty in this 
sample, to determine whether single‐
item performance measures are good 
indicators of multidimensional frailty, 
and to estimate the association between 
frailty and 6‐month mortality.
Gait speed frailty was the strongest 
predictor of mortality in a population 
with CAD and may add to traditional 
risk assessments when predicting 
outcomes in this population.
Boxer  
et al. [14]
Prospective 
cohort/60 patients
To assess the distance on the 6‐min 
walk test (6MWT) as a measure of 
frailty in 60 older HF patients (ejection 
fraction <or= 40%) compared with 
frailty phenotype (FP).
The 6MWT may be useful to identify 
frailty and those in transition to frailty.
Dumurgier 
et al. [15]
Prospective cohort 
study/3208 men and 
women
Study the relation between low 
walking speed and the risk of death 
in older people, both overall and with 
regard to the main causes of death.
Slow gait speed was associated with 
a threefold increase in cardiovascular 
mortality over 5 years but no 
difference in death due to cancer or 
death due to other causes, implying a 
specific effect of frailty on CVD.
Ekerstad  
et al. [5]
Prospective 
cohort/307 patients
To analyze how frailty predicts 
short‐term outcomes for elderly 
non‐ST‐segment elevation myocardial 
infarction patients.
Frailty is strongly and independently 
associated with in‐hospital mortality, 
1‐month mortality, prolonged 
hospital care, and the study’s primary 
composite outcome which included 
endpoints like all‐cause mortality, 
reinfarction, revascularization, and 
even dialysis in older patients after 
non‐ST elevation myocardial infarction 
(NSTEMI).
Table 2. Effect of frailty on cardiovascular disease.
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2. Pathophysiology
The pathophysiology of CVD and frailty relates to a baseline chronic inflammatory state [17–20]. 
This phenomenon is caused by a metabolic imbalance in the body, hereby systemic demand is 
not met by metabolic supply, and consequently the body becomes primarily catabolic, oxidative 
stress increases, and ultimately a low‐level inflammatory phenotype is established [18, 21–28].
Multiple diseases place systemic stress demands on the body [1] that in turn leads to the 
inability of the body to keep pace with the demands of daily living, such as thermoregulation, 
aerobic respiration, glycolysis, and oxidative phosphorylation [17, 22, 29]. As a consequence 
of this baseline mismatch between the body’s demand and its ability to supply, the body 
enters a pro‐catabolic state and begins to metabolize itself for nutrient utilization [17, 25]. 
During this state, more inefficient systems are used to produce energy, and weakness and 
weight loss occur [30]. A pro‐catabolic state is frequently seen in both CHD and frailty and 
leads to, as we already know exists in frailty, a pro‐inflammatory state [18, 24].
The aforementioned pro‐inflammatory state is highlighted by the presence of elevated inflam‐
matory markers. There are markers specific to frailty and others that are common between CVD 
and frailty. Interleukin (IL)‐6 is the most consistently seen inflammatory marker in patients with 
frailty, and is thought to be central to the pathogenesis of the phenotype [18, 21, 24, 26–28]. Studies 
have reported seeing elevated plasma uric acid, D‐dimer, white blood cells (WBCs), erythrocyte 
sedimentation rate (ESR), triglycerides, homocysteine, glucose, hemoglobin A1C (HbA1c), cre‐
atinine, cystatin C, insulin‐like growth factor (IGF)‐1, fibrinogen, von Willebrand factor, factors 
VIII and IX, oxidized proteins, protein carbonylation, as well as decreased vitamin D and testos‐
terone in patients with frailty [31]. In order to highlight the common role inflammation plays in 
both CVD and frailty, we can appreciate that elevations of C‐reactive protein (CRP), factor VIII, 
and D‐dimer are commonly seen even after correction of CVD [32]. Particularly, D‐dimer, CRP, 
IL‐6, and tumor necrosis factor (TNF)‐alpha will be discussed where pertinent.
3. Frailty and hypertension (HTN)
Though not all frail patients are hypertensive, there is some evidence to suggest that HTN is 
independently associated with frailty [33]. The mechanism behind this finding is further elu‐
cidated by the fact that frail patients have a decreased ability to use adenosine triphosphate 
(ATP) [23, 29, 34]. This leads to a decreased ability of smooth muscle to use ATP to pump 
calcium back into the sarcoplasmic reticulum, which is marked by a slower rate of decay 
of the calcium transit. In practical terms, this means the blood vessels of frail patients have 
decreased compliance and difficulty relaxing, which leads to HTN.
The renin‐angiotensin‐aldosterone system (RAAS) is one of the primary systems used by the 
body to regulate blood pressure (BP) (Figure 1) [35, 36]. Chronic inflammation directly stimulates 
RAAS, which causes HTN [37]. Since frail patients have persistently increased inflammation, 
stimulating RAAS, they are more likely to develop HTN. Thus, there is a direct link between the 
chronic inflammation phenotype and HTN in frail patients.
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Evidence from randomized controlled trials over the past decade indicates there is benefit 
to treating hypertension in older patients [38, 39]. This is inconsistent with earlier observa‐
tional and subgroup analyses of previous randomized control trials which were inconclusive 
[40, 41]. The HYVET trial in 2008 specifically focused the treatment of hypertension in elderly 
patients and found that antihypertensive treatment in patients older than 80 was benefi‐
cial [39]. In 2015, the Systolic Blood Pressure Intervention Trial (SPRINT) was undertaken. 
This trial should not be confused with the Sarcopenia and Physical Frailty in Older People: 
Multicomponent Treatment Strategies (SPRINTT) trial, which aims to provide a clear opera‐
tional definition of physical frailty and assess the impact a multi‐component intervention has 
on its progression [42]. The SPRINT trial showed that among patients >50 years old, lowering 
BP to <120 mmHg, particularly in the elderly, was associated with a significant decrease in 
mortality compared to a target of less than 140 mmHg at 5 years (5.2% vs. 6.8%; hazard ratio 
(HR): 0.75; 95% confidence interval (CI): 0.64–0.89, p < 0.001) [38]. Of note, patients who were 
>75 years old tended to fare better than younger patients. Taken together, this suggests that 
all elderly patients benefit from antihypertensive treatments, but there is an important caveat 
to both of these studies: enrolled patients tended to be relatively healthy patients and specifi‐
cally excluded patients with heart failure, stroke, and end‐stage renal disease [35, 38].
Figure 1. Renin‐angiotensin‐aldosterone system. ACE I, angiotensin‐converting enzyme inhibitor; ACE‐2, angiotensin‐
converting enzyme‐2; Ang, angiotensin; BK, bradykinin; BP, blood pressure; HFpEF, heart failure with preserved ejection 
fraction; JG, juxtaglomerular; LV, left ventricle; LVEDV, left ventricular end diastolic volume; LVH, left ventricular 
hypertrophy; NO, nitric oxide; PAI‐1, plasminogen activator inhibitor‐1; SNS, sympathetic nervous system.
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The exclusion criteria for HYVET and SPRINT raise concern that their findings may not 
be generalizable to frail patients [43]. A subgroup analysis of patients enrolled in HYVET 
addressed this concern [44]. Participants in both the control and treatment groups were given 
a frailty index according to 60 different variables. The impact of the frailty index on subse‐
quent risk of stroke, mortality, and cardiac events was found to be non‐significant, suggesting 
that benefits associated with BP lowering were conserved in frail patients. A frailty index was 
calculated for SPRINT participants using a similar set of 36 variables [45]. The frailty index 
distribution among the participants was comparable to general population cohorts. This sug‐
gests the heterogeneity of frailty among participants is similar to the general population.
Another 2015 report as a part of the Zwolle Outpatient Diabetes Project Integrating Available 
Care‐34 (ZODIAC‐34) cohort study, this time including all‐comers, confirmed what observa‐
tional studies had shown: for all‐cause mortality (especially frail patients), there was an inverse 
relationship between blood pressure and all‐cause mortality with a hazard ratio for systolic 
blood pressure of 0.92 (95% CI: 0.87–0.98) and 0.83 for diastolic blood pressure (95% CI: 0.73–
0.93) [46]. This suggested that among all patients >75 years of age, this time including those with 
less than 1 year life expectancy and DM, lower BP was associated with an increase in mortality. 
Contiguously, intensive lowering of BP in patients with low gate speed (a commonly used proxy 
for frailty) did not reduce mortality and the rate of CVD events (p = 0.05, 0.28, respectively) [47].
4. Frailty and lipids
The metabolism of lipids has been shown to affect aging, such that having a high‐density lipo‐
protein (HDL) level above 70 mg/dL is referred to as longevity syndrome. The Invecchiamento 
e Longevità nel Sirente (ilSERENTE) study showed that the HDL levels of the patients in their 
study who died during follow‐up were significantly lower than the levels of the survivors. 
This finding contributed to the understanding of the effect of HDL on lifespan, highlighting 
the role of lipid metabolism in decreasing mortality in the frail, elderly patient [48]. Another 
study of the same group of patients showed that, among frail patients, those with the high‐
est HDL levels had the best functional states [49]. To further support this idea, another study 
done in 2015 supported frailty as an independent risk factor for various diseases along the 
CVD spectrum. A low HDL level was one of the parameters [50]. As a part of the Longitudinal 
Aging Study Amsterdam, it was described that a lower total cholesterol was related to a higher 
rate of decline on information‐processing speed indicating, ultimately, that lower total choles‐
terol may be considered to be a marker of frailty and predictive of lower cognitive function in 
the elderly [51]. As described earlier, there has been significant study regarding the relation‐
ship between frailty, HDL status, and its effect on mortality. Conversely, the relation between 
low‐density lipoprotein (LDL) levels and frailty has yet to be established. Also, whereas the 
effect of lipids in the frail patient has been studied, the effect of frailty on the patient with a 
lipid disorder has yet to be established.
There has been speculation upon the metabolism of lipids in the frail patient. As there is a 
pro‐inflammatory milieu in the frail patient, this inflammation may affect lipid metabolism 
and, hence, lipid profiles in those who are frail. There may also be some correlation between 
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dysfunctional lipid metabolism due to endocrine dysregulation evidenced by lower IGF‐1 
and growth hormone levels in frail patients, lower HDL levels, and resultant poorer outcomes 
in CHD [52, 53]. A study on metabolic syndrome and disability showed a correlation between 
high triglycerides and a limitation in mobility and activities of daily living [54]. Overall, the 
effect of frailty, its pro‐inflammatory state, and the collective effect on lipids seems to be con‐
tiguous with an elevation in triglycerides (TGs) and a decrease in HDL likely contributing to 
the elevated CVD risk in the frail population.
5. Frailty and atrial fibrillation (AF)
The up‐regulation of the RAAS system in frail patients, as mentioned earlier, mediates an 
up‐regulation of endothelin‐1, which in turn mediates an increase in cardiac fibrosis [55]. 
Cardiac fibrosis, in turn, increases the likelihood of AF by disrupting the cardiac neurocon‐
duction pathways [23]. Additionally, frailty may be an independent risk factor for AF [46] due 
to a decreased ability to modulate heart rate, resulting in an increased likelihood of a patient 
developing AF [56, 57]. Additionally, an increased calcium influx, as discussed earlier, causes 
changes in the trans‐cellular membrane potential, which in turn makes a patient more likely 
to develop AF [23].
Frail patients have a 4.4 times higher chance (95% CI: 2.104–9.080, p < 0.001) of having AF com‐
pared to the general population [57]. Additionally, Polidoro et al. found that even after adjust‐
ing for age, sex, CVD, and CVD risk factors, AF was associated with a fourfold increase in 
frailtyhighlighting the relation between frailty and AF [58]. Additional evidence supporting 
the link between frailty and AF is the impairment of autonomic control vis‐à‐vis decreased 
heart rate variability which often precedes episodes of paroxysmal AF [57]. Similarly, there is 
decreased heart rate variability in frail patients.
AF has a significant impact on outcomes, including mortality, in frail patients [59]. Nguyen et 
al. found that in patients with AF, there was a 2.69 times higher risk of death in frail patients 
over a 6‐month period after hospitalization (HR: 2.69, 95% CI: 1.53–4.74). This relationship 
held even after correction for potential co‐founders (HR: 2.33; 95% CI: 1.31–4.14). It may be 
plausible to infer that AF also causes significant risk for cognitive decline to these patients see‐
ing as they are already at an increased risk for microbleeds as discussed subsequently in the 
section on cerebrovascular disease. Furthermore, the strong risk of stroke and TIA outlined in 
the subsequent text is indubitably linked with AF [60].
Despite the increased risk of death with AF, frail patients have an eightfold less likelihood of 
being discharged home on an oral anticoagulant after hospitalization [57]. In fact, frailty is 
the third most cited reason for not prescribing an oral anticoagulant. This makes the report 
by Granzera et al. more pertinent as the population ages [61]. In this study, he provides an 
approach to deciding if oral anticoagulation is appropriate in elderly frail patients (Figure 2).
Granziera et al. also discussed what factors should go into making the decision of whether to 
use warfarin or novel oral anticoagulants (NOACs) in frail patients [61]. Severe renal impair‐
ment, severe liver impairment, and poor adherence favored the use of warfarin. The exceptions 
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Figure 2. Decision algorithm for use of oral anticoagulants in elderly frail patients (<75 vs. ≥75 years). Adapted from 
Granziera et al. [61].
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to favoring warfarin in renal impairment are apixaban and edoxaban, both of which may be 
prescribed in patients with compromised renal function. Decreased renal and hepatic clear‐
ances have minimal effect on warfarin. In patients at risk for poor compliance, their risk for 
stroke will not revert to baseline if a dose is missed. For patients with decreased mobility, 
they are less likely to comply with nutritional changes for warfarin and have polypharmacy; 
NOACs are the better choice for improved compliance.
Frail patients may have less of a benefit from device therapy than healthy patients [57]. In a 
combined analysis of four clinical trials, the benefits of implantable cardioverter defibrillators 
were inversely proportional to the number of comorbidities. This line of thought was further 
supported by a retrospective study of 83,792 undergoing ICD implantation in which frail 
patients had a 22% risk of mortality at 1 year compared to 12% overall.
6. Frailty and cerebrovascular disease
Several studies have indicated that frailty is associated with low cognitive performance. This 
is attributed to multiple causes including increased rates of Alzheimer’s disease (AD), mild 
cognitive impairment, and a distinct subtype of frailty—cognitive frailty [62, 63]. Cognitive 
frailty is a clinical syndrome found in elderly patients without AD or other dementias, and 
occurs concurrently with physical frailty [63]. The key feature differentiating this syndrome 
from AD and other dementias is its potential for reversibility. The proposed mechanism 
for cognitive frailty is similar to physical frailty—a decrease in physiological reserves for 
responding to systemic stressors that manifests as an erosion of homeostatic mechanisms. 
The erosion of homeostatic mechanisms seen in cognitive frailty is manifested as β‐amyloid 
accumulation. These changes are independent other causes of dementia such as vascular and 
Alzheimer’s dementia.
Frail patients were also more likely to have any form of dementia (HR 1.85; 95% CI: 1.01–3.40) 
and vascular dementia in particular (HF 2.68; 95% CI: 1.16–7.17) [62]. Frail patients are 3.38 times 
(95% CI: 2.37–4.81, p < 0.001) more likely to have a stroke or TIA than non‐frail patients [60]. 
This association with cerebrovascular disease extends to include pre‐frail patients, who have a 
1.98 times greater risk of having a stroke versus non‐frail patients (95% CI: 1.53–2.57, p < 0.001). 
Another manifestation of cerebrovascular disease, cerebromicrobleeds, is one of the primary 
lesions responsible for vascular dementia. When the number of lesions is low (only one or two), 
there is usually no clinical evidence of microbleed, but when there is a larger lesion burden, 
patients present with stroke or dementia [64]. Even when adjusted for age, sex, and presence of 
vascular risk factors (CHD, chronic kidney disease, and global cognitive impairment), the lesion 
number was positively correlated with the severity of physical frailty. Chung et al. also found 
that the severity of physical frailty was positively correlated with proportion of cerebromicro‐
bleeds present in the deep and infratentorial regions of the brain.
Furthermore, a study performed on patients undergoing carotid endarterectomy (CEA) 
using the American College of Surgeons National Surgical Quality Improvement Program 
(NSQIP) database from 2005 to 2011 showed that frailty is a predictor of increased stroke, 
Frailty and Cardiovascular Disease
http://dx.doi.org/10.5772/intechopen.69877
205
mortality, myocardial infarction, and length of stay after CEA, further supporting the idea 
that CVD and frailty are strongly interlinked with frail patients suffering poorer outcomes 
postintervention [65].
6.1. Inflammatory markers in CHD
The relationship between frailty and CHD is one that has been extensively studied as well. 
Chronic inflammation is a shared mechanism between atherosclerosis and frailty [18, 66, 67]. 
In Libby et al.’s strong and well‐cited review article, they show that, in addition to plaque 
characteristics, acute coronary syndromes are also caused by a chronic inflammatory state 
[59]. This link is most strongly seen by four markers of inflammation shared by both frailty 
and coronary vascular disease: IL‐6, CRP, fibrinogen, and D‐dimer [26, 27].
Hunter et al. made the strong case that IL‐6 is a keystone mediator of systemic inflammation 
in multiple disease processes, especially CVD [28]. There have been numerous other stud‐
ies linking IL‐6 and CHD [18, 66, 67]. This suggests that IL‐6 is central to the immunogenic 
dysregulation that accounts for the disease burden suffered by patients with both CVD and 
frailty [28]. Another significant marker of chronic inflammation shared between both CHD 
and frailty is CRP [26, 27]. Like IL‐6, this marker is elevated in frailty even when CHD is 
accounted for [32].
Fibrinogen is an acute‐phase reactant shown to be elevated with chronic inflammation and 
is strongly correlated with both frailty and atherosclerosis [26, 66]. Elevated fibrinogen is an 
independent risk factor for CVD events [66]. The mechanism is thought to be caused by fibrin‐
ogen affecting the plaque phenotype, causing it to be more permeable, able to accumulate oxi‐
dized LDL, increase platelet reactivity, and aggregation. A direct association between frailty 
and fibrinogen has been observed independent of chronic disease states [26].
Similar to fibrinogen, D‐dimer fragments are an independent risk factor for CHD to the 
point where they are considered a biomarker for atherothrombosis [66]. Moreover, elevated 
D‐dimers are also independently associated with frailty [32].
7. Frailty and CHD
A meta‐analysis of 54,250 elderly individuals with a mean follow‐up of 6.2 years showed that 
the presence of atherosclerotic CVD was associated with the coexistence of frailty syndrome 
with an odds ratio of 2.7–4.1 [6]. The relationship between CVD and frailty is significantly 
bidirectional [6, 60]. This is highlighted by the twofold increase in mortality among frail CHD 
patients compared to non‐frail patients even when adjusted for age and comorbidities [68]. In 
the Women’s Health Initiative Study, women with CHD were more likely to become frail over 
the subsequent 6 years; likewise, the Health, Aging, and Body Composition Study showed 
that older adults with frailty were more likely to develop CHD. This same study showed that 
the presence of frailty, assessed by gait speed, was associated with an increased risk of inci‐
dent CVD. After adjustment for potential confounding factors, a slower gait was associated 
with an increased incidence of CVD events and all‐cause mortality compared with individuals 
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having higher walking speed [69]. Furthering the complexity of this disease interplay is the 
fact that patients with both frailty and CHD have a higher frequency of multivessel disease 
and left main disease (74%) than non‐frail patients (60%) and moderately frail (68%) patients 
(p = 0.019) [70]. These differences persisted even after correcting for age and gender (p = 0.005). 
The wealth of evidence clearly defines the effect of frailty upon CHD.
Interestingly, atherogenesis is also affected by sarcopenia. This effect is partially due to the 
replacement of muscle with adipose tissue, and partially to the neurohumoral dysregula‐
tion and decreased mobility brought on by sarcopenia [71–73]. Atherogenesis is worsened 
by the presence of sarcopenia and frailty in humans as evidenced by the association between 
carotid atherosclerosis, arterial stiffness, and sarcopenia [6]. It, therefore, seems natural that 
frail patients fare worse after an acute CHD event compared to non‐frail patients. This notion 
was validated by Dodson et al., who found that at 1 year after an acute CHD event, older 
adults with slow gait speed (<0.8 m/s measured 1 month after the event) were more likely to 
die or be re‐admitted to the hospital than those with faster speeds (35.4% vs. 18.5%; p = 0.006) 
[74]. However, it is important to note that the majority of these events were re‐admissions—
not death.
Regarding interventions, there has been an extensive amount of investigation into whether 
coronary artery bypass grafting (CABG) is better than percutaneous coronary intervention 
(PCI) in frail patients. Fifty‐six percent of frail patients who underwent CABG had postop‐
erative complications compared to seventeen percent of those who were non‐frail (p < 0.001) 
[75]. Frailty was also an independent predictor of in‐hospital mortality after CABG (OR 1.8; 
92% CI: 1.1–3.0). Similarly, PCI also carried significant risks. Frailty was associated with a 
longer hospital stay (HR 4.8, 95% CI: 1.4–16.3; p = 0.013), higher 30‐day mortality (HR 4.8, 95% 
CI: 1.4–16.3; p = 0.01), and higher 1‐year mortality (HR 5.9, 95% CI: 2.5–13.8; p < 0.001) [76, 77]. 
Importantly, there is evidence that there is no significant difference in change in frailty at 
30 months between CABG and PCI (p = 0.090) [78]. In patients ≥75 years old treated with 
either PCI or CABG, there was a significantly different trajectory in their frailty score at 30 
months (0.188 vs. 247, respectively) and at baseline (0.164 vs. 0.189, respectively; p = 0.041). 
Including frailty as part of the three‐tiered criterion in the assessment of a patient under‐
going PCI improved the discriminatory ability of the Mayo Clinic risk score [79]. Of great 
importance is the decision as to which modality of intervention is most effective in the frail 
population with obstructive coronary artery disease (CAD). Although we suspect that being 
less invasive in frail patients may be preferable, a prospective, randomized trial in the frail 
population addressing this quandary, as well as whether revascularization impacts frailty, 
would be beneficial.
8. Frailty and peripheral arterial disease (PAD)
Clearly, PAD is a pandemic condition that could potentially lead to the literal loss of life and 
limb. It manifests as tissue hypoperfusion caused by acute insult upon a limb with preexist‐
ing underlying atherosclerosis. This disease process is a significant cause of morbidity and 
mortality in both the frail and non‐frail populations [80, 81].
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Frailty has been shown to be associated with and worsen outcomes in patients with PAD. A 
study of the participants >50 years of age in the National Health and Nutritional Examination 
Survey (NHANES) showed that, in multivariable multinomial logistic regression models, 
ankle brachial index (ABI) <0.9 predicted frailty and pre‐frailty. A higher prevalence of frailty 
was seen in participants with ABI ≥1.4. Frailty predicted general and CVD mortality in par‐
ticipants with ABI <0.9. Hence, this study suggested that frailty mediates increased morbidity 
and mortality in PAD [82]. A cross‐sectional study was carried out in a geriatric population 
of ≥65‐year‐old residents of Taichung, Taiwan, in June 2009 to assess the association between 
frailty and subclinical PAD. It reported findings suggesting that frail individuals had a signifi‐
cantly increased risk for subclinical PAD with an odds ratio of 3.168 [83]. In a study assessing 
gait in patients with PAD versus non‐PAD both with and without frailty, the pre‐frail group 
defined by the Fried Frailty Index had a diminished difference between study groups. This 
indicated that pre‐frail patients have a poor functional status overall, which may overshadow 
the level of dysfunction imposed upon them by PAD alone [84].
Another study assessing the effect of frailty on outcomes after vascular surgery showed that 
frailty, assessed by the modified Frailty Index (mFI), predicted mortality in patients under‐
going open procedures and Clavien‐Dindo class IV (life‐threatening) complications for both 
open and endovascular abdominal aortic aneurysm repairs [85]. Affecting disposition and, 
hence, patient wellness and health‐care expenditure, frailty also increases the propensity of 
home‐dwelling patients classified as frail to be discharged to a facility other than their home 
after elective vascular interventions [86]. There is also evidence to support the idea that frail 
females are potentially at the highest risk of death after vascular surgery, suggesting that 
female gender may be an additive risk factor [87].
9. Frailty and heart failure
The pathogenesis of HF has significant overlap with the processes leading to the frailty phe‐
notype [17, 88]. With HF, much like frailty, the metabolic demands of the body outstrip physi‐
ologic reserves. The findings of Lavie et al. likewise show that a loss of fat (reserves) signals a 
worsening prognosis in HF [30].
Frail patients and patients with HF consistently have a similar biochemical profile of ele‐
vated CRP and interleukin‐6, which in turn promote mitochondrial dysfunction [18, 22, 31]. 
Mitochondrial dysfunction produces excessive reactive oxygen species producing a pro‐
apoptotic intracellular environment. In the case of HF, apoptosis of cardiomyocytes fosters 
a local pro‐inflammatory atmosphere, leading to cardiac fibrosis and ultimately decreased 
contractility. Likewise, when applied to skeletal muscle, this process causes sarcopenia, one 
of the hallmarks and precursors of frailty.
The likelihood of a frail patient to manifest HF is 8.76 times higher than that of a non‐frail 
patient and, compared to any other element of CVD, HF is the most strongly linked with 
frailty [60, 89]. However, it should be noted that frailty is not limited to geriatric heart failure 
patient, and been observed in up to one‐third of younger patients with HF [68]. The prevalence 
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of frailty among heart failure patients is important because frailty is an even stronger predictor 
of mortality than is HF per se [88]. Cacciatore et al. assessed the role frailty had on mortality 
in HF patients (n = 1139) over a 12‐year period compared to patients without CHF (n = 120) 
and found that frailty was independently associated with mortality in HF (HR 1.48, 95% CI: 
1.04–2.11; p = 0.0032) and control group patients (HR 1.36, 95% CI: 1.17–1.57; p < 0.001), prov‐
ing that it indeed was a more important predictor of mortality than HF itself [12]. Lupon et al. 
found that among 622 outpatient HF patients, frailty was an independent predictor of mortal‐
ity even after adjustment for HF (HR 2.09, 95% CI: 1.11–3.92; p = 0.022) [90].
Discerning which patients are frail versus non‐frail also has an impact on clinic resources. Frail 
patients versus non‐frail patients in one study had a 92% increase in Emergency Department 
(ED) visits (HR 1.92, 1.60; 95% CI: 1.30–2.83) and 65% increased risk for hospitalizations (HR 
1.65; 95% CI: 1.17–2.35) [91]. Of note, there was no significant association between outpatient 
visits in HF patients and frailty. This raises the question as to whether or not more intensive 
outpatient management of frail HF patients would decrease ED and hospital utilization.
One possible intervention to decrease the amount of hospital utilization in frail patients and, 
moreover, improve their morbidity and mortality is specifically resistance exercise [92]. As 
noted by Lavie et al., there is compelling evidence that muscle mass and muscle strength are 
protective in HF patients [93]. Moreover, a lack of muscular fitness overall is a strong determi‐
nant of cardiac cachexia which, as mentioned earlier, may be seen as a classification of frailty. 
There is evidence to suggest that maximal aerobic power, a measure of frailty, decreases with 
age, due to a decrease in cardiac output, and is exacerbated by CVD. Importantly, this is a 
measure of frailty which could be addressed with an increase in muscle mass and anaerobic 
exercise [94]. It is important to note that resistance training is the most well‐validated coun‐
termeasure to slow the decline of muscle mass and muscle strength, even in frail patients [92]. 
By slowing the decline in muscle strength, the decline into frailty is consequently retarded. 
Taken together, this evidence points to muscle bulk, or the lack thereof, as being a significant 
marker of disease progression in HF and element of CVD.
The choice of pursuing advanced therapeutic options in the frail population with HF is a 
difficult one. As Joyce points out, HF itself and its ensuing sequelae can simulate the frailty 
phenotype [95]. Discerning between frailty caused specifically by HF and frailty attributable 
to non‐CVD causes has significant implications in this selection of patients for destination 
therapy with left ventricular assist devices (LVADs). In patients with HF as the primary driver 
of his or her frailty, implantation of an LVAD led to restoration of aberrant cardiac output and 
metabolism. Flint et al. sorted out frail patients receiving an LVAD into three groups: LVAD‐
responsive, LVAD‐independent, and LVAD‐intermediate. In the LVAD‐responsive group, 
whose frailty was primarily due to HF, implantation of LVAD caused a significant decrease in 
post‐LVAD frailty as measured by hand‐grip strength compared to both the LVAD‐intermedi‐
ate and LVAD‐independent patients. These LVAD‐responsive patients may be more accurate 
representatives of cardiac cachexia versus frailty.
Frailty in the heart‐transplant (HT) population has more significant and far‐reaching impor‐
tance. Frail patients who underwent HT in one study had a 1‐year survival rate of 52 ± 23% 
versus 100% in the non‐frail control arm. This has significant implications in the way HT 
Frailty and Cardiovascular Disease
http://dx.doi.org/10.5772/intechopen.69877
209
therapy is allocated. This is a realm that requires more study, though studies will be sparse 
given the requirements for HT approval, including appropriate performance on pre‐HT 
cardiopulmonary testing, in which frail and pre‐frail patient would likely have suboptimal 
results.
10. Frailty and valvular heart disease (VHD)
In industrialized countries, the prevalence of VHD is estimated at 2.5%. Degenerative calcifi‐
cation seems to augment the prevalence of VHD markedly after the age of 65 years, particu‐
larly regarding aortic stenosis (AS) and mitral regurgitation (MR). These two disease entities 
account for three in four cases of VHD. Also contributing to the incidence of VHD is infec‐
tive endocarditis, the incidence of which is approximately 30 cases per million individuals 
per year worldwide. Finally, rheumatic heart disease (RHD) is another very significant con‐
tributor to the incidence of VHD and still represents a significant health burden with over 
15 million cases of RHD worldwide, 282,000 new cases, and 233,000 deaths annually [96]. 
Health‐care expenditure for these disease entities is substantial. In fact, US expenditure esti‐
mates close to $2 billion annually for symptomatic and asymptomatic aortic VHD, and $2.6 
billion for symptomatic and asymptomatic mitral VHD [97, 98].
Patients who meet indications for VHD surgery are frequently not offered surgery due to 
prohibitive risk features. As an example in the mitral VHD population, among patients who 
meet the current indications for surgical treatment of MR, almost 50% are not offered therapy 
due to several factors, including high surgical risk from comorbidities and frailty associated 
with advanced age [99, 100]. Importantly, though some patients may tolerate a surgical pro‐
cedure, meaningful functional recovery is not achieved if they demonstrate marked frailty 
prior to the intervention [101]. Unfortunately, such patients are left with few clinical options, 
resulting in frequent referrals to palliative care and hospice programs. Fortunately, as we now 
know, patients earlier deemed inoperable or high risk for conventional VHD surgery have 
minimally invasive options to address their comorbid state. These include transcatheter aortic 
valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), and Mitraclip. 
These procedures may be the ones most suitable for the frail population as they are part of the 
aforementioned patient populations that would otherwise be left without options. Currently, 
of the interventions for VHD that are performed, the three mentioned earlier are the ones that 
have the most impact on the frail population.
In a study aimed at studying inflammatory markers in patients undergoing TAVR in an 
attempt to estimate preoperative risk, two inflammatory markers were studied. Neopterin, 
a pteridine synthesized by activated macrophages, and immune activation‐mediated trypto‐
phan and its subsequent degradation had both been shown prior to be associated with frailty 
and chronic disease. Ultimately, increased immune activation and associated tryptophan deg‐
radation underscored the prognostic role of baseline inflammation for outcome in patients 
with severe AS undergoing TAVR [102]. The aforementioned inflammatory markers like IL‐6, 
TNF‐alpha, D‐dimer, and CRP have not yet been studied in the frail population in regard to 
outcomes in VHD but may prove to be valuable area of further research.
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Frailty is well known in the VHD population to be associated with poorer outcomes when 
compared to non‐frail patients. Patients with a moderate to severe degree of frailty (defined 
as requiring assistance to ambulate or attend to their own bodily needs, or a modified Rankin 
score 4) are generally considered high risk for valvular surgery [103]. In a study conducted by 
Sepeheri et al., frailty had a strong positive relationship with the risk of major adverse cardio‐
vascular and cerebrovascular events (MACCE) (odds ratio, 4.89; 95% confidence interval, 1.64–
14.60) [104]. Relationships were stronger in older patients undergoing TAVR than younger 
patients undergoing CABG and VHD surgery (hazard ratio for frailty in TAVR, 3.31–4.89 vs. 
hazard ratio for non‐TAVR, 1.10–3.16). One single‐center experience of all cardiac operations 
demonstrated frailty to be an independent predictor of in‐hospital mortality, institutional dis‐
charge, and reduced midterm survival [105]. In a study assessing the effect of frailty on mor‐
tality, length of stay (LOS), and discharge destination in patients post‐TAVR, Chauhan et al. 
showed that frailty portended an increase in LOS and mortality [106]. Additionally, a study 
assessing preoperative computed tomography (CT) scans that are done as part of the workup 
for transcatheter therapeutic interventions for VHD shows that these CTs have proven useful 
in measuring the patient’s skeletal mass index (SMI) and, thus, preoperative sarcopenia. This 
correlated directly to length of stay more strongly than the frailty index [107].
Many of the frail patients afflicted with MR, however, tolerate MitraClip and are able to 
recover from the femoral venotomy and general anesthesia required for this procedure. In 
one study assessing effectiveness of transcutaneous mitral valve repair with Mitraclip in 564 
patients, frailty was noted in 57% of patients. The procedural success rate, nonetheless, was 
91% defined as MR less than or equal to grade 2 and surviving the hospital stay. A majority 
of patients were discharged home with moderate or less MR than prior [108]. Patients with 
severe frailty who are bedridden and/or require constant nursing care may be too disabled to 
achieve meaningful benefit from MitraClip and may also be considered prohibitive for TAVR 
[101]. This, though, has yet to be assessed prospectively.
The interesting aspect of frailty in VHD is that the novel interventions in this field are gener‐
ally aimed to treat non‐operable or high, prohibitive risk individuals. Frail patients comprise 
a significant portion of this population indicating that understanding how best to treat these 
patients is of significant import for the field in its gestalt. As this field continues to develop 
more prolifically, addressing the frail patient will prove to be an area of in‐depth study. Many 
practitioners share the belief that current interventions prove to reverse certain aspects of 
frailty but this has yet to be studied in a prospective trial.
11. Conclusions
Frailty is a significant disease entity affecting a myriad of clinical situations. How it affects the 
spectrum of CVD has been an area of interest and study for a number of years. With the advent 
of novel procedures in the realm of VHD and the expansion of patient populations now being 
considered as candidates for interventions, the topic of frailty, its interplay with CVD, and 
how it affects outcomes in patients with CVD are of the utmost import. As discussed earlier, 
current risk scores for patients undergoing cardiovascular surgery (STS and euroSCORE) have 
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yet to include frailty as official criteria in their scoring systems, yet many practitioners still note 
frailty to be a condition predisposing patients to unfavorable outcomes and, thus, precluding 
them from interventions.
That frail patient suffers poorer outcomes is significant. From postintervention mortality to 
disposition postdischarge, frail patients perform suboptimally when compared to their non‐
frail counterparts. The generalized debility to which frail patients are predisposed may make 
them less tolerant of therapeutic postintervention treatments that would otherwise improve 
their outcomes, such as physical therapy and progressive exercise training. Their subclinical 
inflammatory state may further prevent wound healing and resolution. Also, their comorbid 
conditions may prevent complete healing and recovery as well. These hypotheses have not 
yet been studied and warrant further investigation for the purpose of elucidating ways to 
counteract the aforementioned poorer outcomes experienced by frail patients.
Frailty can be treated, potentially, with specific modalities, such as exercise, protein‐calorie 
supplementation, vitamin D, and reduction of polypharmacy [109]. This shows that, although 
frailty is incredibly significant and has undeniable impacts on morbidity and mortality, it is 
something that is potentially reversible. With further study and therapeutic interventions tai‐
lored specifically to the frail patient, we may be able to expand our indications and improve 
the quality of life for a patient population known to suffer with a disease process different 
from any other.
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